ITGA2B and cerebral infarction: A study by Cho YD et al. found that the 10.5% of their patients received an IA GP IIb/IIIa inhibitor during the treatment of ruptured intracranial aneurysms, and although a high rate of recanalization (87.2%) was obtained in these patients, intracerebral hematoma occurred in 5.1% and cerebral infarction developed in 20.5% of these patients [4].